- Previous Close
18.08 - Open
17.93 - Bid 18.10 x --
- Ask 18.11 x --
- Day's Range
17.90 - 18.16 - 52 Week Range
17.60 - 30.79 - Volume
4,156,787 - Avg. Volume
6,596,428 - Market Cap (intraday)
10.576B - Beta (5Y Monthly) 0.32
- PE Ratio (TTM)
12.49 - EPS (TTM)
1.45 - Earnings Date --
- Forward Dividend & Yield 1.50 (8.28%)
- Ex-Dividend Date Jun 14, 2024
- 1y Target Est
--
Sunflower Pharmaceutical Group Co.,Ltd engages in the research and development, manufacturing, and marketing of Chinese patent medicines in China and internationally. The company produces chemical and biological medicines, and health care products. It also provides products covering various therapeutic areas, including pediatrics, gynecology, digestive system, respiratory and cold, rheumatic bone disease, and cardiovascular and cerebrovascular; supplements; and antibiotics and children's medicinal products. The company sells its products under the Sunflower and Little Sunflower brands. Sunflower Pharmaceutical Group Co.,Ltd was founded in 2005 and is headquartered in Harbin, China.
www.kuihuayaoye.com5,776
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 002737.SZ
View MorePerformance Overview: 002737.SZ
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 002737.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 002737.SZ
View MoreValuation Measures
Market Cap
10.58B
Enterprise Value
8.39B
Trailing P/E
12.49
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.41
Price/Book (mrq)
2.36
Enterprise Value/Revenue
1.89
Enterprise Value/EBITDA
7.87
Financial Highlights
Profitability and Income Statement
Profit Margin
19.29%
Return on Assets (ttm)
9.08%
Return on Equity (ttm)
18.76%
Revenue (ttm)
4.43B
Net Income Avi to Common (ttm)
854.79M
Diluted EPS (ttm)
1.45
Balance Sheet and Cash Flow
Total Cash (mrq)
2.2B
Total Debt/Equity (mrq)
0.25%
Levered Free Cash Flow (ttm)
-205.43M